Article

Complete Response for Adding Pyrotinib to Pembrolizumab and Lenvatinib for HER2 Positive Advanced Intrahepatic Cholangiocarcinoma

2022-04-13

Abstract excerpt

<h4>Background: </h4> Intrahepatic cholangiocarcinoma (ICC) is a highly lethal hepatobiliary cancer. Only very few patients could undergo surgery. The prognosis of advanced ICC is poor, especially for patients who progressed after first-line chemotherapy, leaving median overall survival less than 10 months. To date, no case has been reported to achieve complete response by targeted therapy and immunotherapy for ad...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 760adfb6-eb2d-53b2-a279-085c12fc48bb
DOI: 10.21203/rs.3.rs-1531884/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Complete Response for Adding Pyrotinib to Pembrolizumab and Lenvatinib for HER2 Positive Advanced Intrahepatic CholangiocarcinomaDOI 10.21203/rs.3.rs-1531884/v1Read

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read

Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burdenSemantic proximity Read

Pathological Complete Response after Pembrolizumab Treatment for Unresectable Perihilar Cholangiocarcinoma with High Microsatellite Instability: A Case ReportSemantic proximity Read

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read

HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.Semantic proximity Read

Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.Semantic proximity Read

Precision Oncology in Cholangiocarcinoma: Two Fusion-Positive Case Reports and a Literature ReviewSemantic proximity Read

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden.Semantic proximity Read

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.Semantic proximity Read

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world studySemantic proximity Read

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.Semantic proximity Read

miR-325-3p Facilitates Tumorigenesis and Acquired Pemigatinib Resistance in Intrahepatic Cholangiocarcinoma via Targeting ADH1B through Epithelial–Mesenchymal Transition and PI3K/AKT SignalingSemantic proximity Read